Flamel Technologies S.A. (ADR) (FLML)
A biopharmaceutical company principally engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications.
Recs
Downthumb. Biotech. Controlled release transport of proteins. Negative cash flow. Slow growth. Risky for longs.
Recs
nano!
Recs
Looks like they finally decided to let go and put their products out there for everyone to enjoy. This should give this company big boost and send them back to where they really belong.
Recs
5.1172 at $111.00 or 21.69 per share. Can't do much worse.
Recs
It would be difficult for me to be more wrong about a stock than I was with this one. I got caught up in the "potential" of their technology and ignored their poor execution.
Recs
Niche in medical technology will pay off.
Recs
THIS STOCK HAS BEEN AT $31.96, BELIEVE ITS ON ITS WAY TO THAT AREA AGAIN
Recs
Never stays above 30, but surely gets there every now and then, so at a price below 10, this is a good bargain.
Recs
Drug release procall for insulin
Recs
Bought at the bottom of their 52 week range. Not sure even that price is justified, but hoping their delivery technology will find new markets.
Recs
As some waver and sell because of fear I am adding to my real position and believe in the long term potential.
Recs
purely a play on the fallen who should get up, even if its to a crawling position....
Recs
Recs
New license with Wyeth for the use of its protein delivery system.
Recs
Powerful technology, activist investors, and 52-low price adds up to a market over-reaction. Buy now sit back, and enjoy the ride. This will return at least 50% in the next year or so.
Recs
The French are now our friends.
Recs
This is an incredibly risky stock in the short term. (Just look at today... down about 20%!) There is a recent research report (out today in abstract form) that has negatively impacted one of their drug trials, though the full report awaits. If you hate volatility, well then just stay away from this for a while, until they prove themselves able to recover. The potential upside is huge, but as many others mention, you could lose everything. I'm still long (though I'm bleeding today!), 2-4 years, could even be longer than that. I'm not confident enough to put any more money into it though. We'll see....
Recs
Negative news at Glaxo has this name oversold. At today's price, I think this will outperform.
Recs
badly beaten up!
Recs

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 56 1 2 3 Next »